However, as the futility boundary was crossed, there is enough data to exclude the association between GLP-1 agonists treatment and pancreatic cancer (considering a difference of 0.1% between treatment groups) (Fig. 3). The gene discussed is GCG; the disease is pancreatic neoplasm.